Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by American Century Companies Inc.

American Century Companies Inc. trimmed its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 79.2% in the second quarter, HoldingsChannel.com reports. The firm owned 5,627 shares of the company’s stock after selling 21,428 shares during the quarter. American Century Companies Inc.’s holdings in Janux Therapeutics were worth $236,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Summit Securities Group LLC acquired a new stake in Janux Therapeutics in the second quarter worth approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics in the second quarter worth approximately $151,000. DNB Asset Management AS acquired a new stake in Janux Therapeutics in the second quarter worth approximately $221,000. Principal Financial Group Inc. acquired a new stake in Janux Therapeutics in the second quarter worth approximately $237,000. Finally, Arizona State Retirement System acquired a new stake in Janux Therapeutics in the second quarter worth approximately $242,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06. Following the sale, the insider now directly owns 7,000 shares of the company’s stock, valued at $296,310. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06. Following the sale, the insider now directly owns 7,000 shares of the company’s stock, valued at $296,310. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the sale, the chief executive officer now directly owns 307,054 shares in the company, valued at approximately $14,219,670.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 393,767 shares of company stock valued at $17,857,979 in the last three months. 35.40% of the stock is currently owned by company insiders.

Janux Therapeutics Stock Up 1.9 %

Shares of NASDAQ:JANX opened at $45.02 on Friday. The company’s fifty day moving average is $43.84 and its two-hundred day moving average is $44.67. Janux Therapeutics, Inc. has a 12-month low of $5.65 and a 12-month high of $65.60. The company has a market cap of $2.33 billion, a P/E ratio of -36.80 and a beta of 3.54.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company had revenue of $8.90 million for the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics’s revenue for the quarter was up 709.1% on a year-over-year basis. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Stifel Nicolaus assumed coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. Scotiabank dropped their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $66.13.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.